Aurinia Pharmaceuticals (AUPH) Accumulated Expenses (2023 - 2026)

Aurinia Pharmaceuticals (AUPH) has 4 years of Accumulated Expenses data on file, last reported at $58.2 million in Q1 2026.

• Quarterly Accumulated Expenses rose 37.41% year-over-year to $58.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.2 million (up 37.41% YoY) and the FY2025 annual result came in at $66.6 million, up 2.54% from the prior year.
• Accumulated Expenses declined to $58.2 million in Q1 2026, from $66.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $66.6 million in Q4 2025 to a low of $42.4 million in Q1 2025.
• A 4-year average of $54.5 million and a median of $50.1 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2025 — Accumulated Expenses advanced 2.54% — and 2026, when it soared 37.41%.
• Tracing AUPH's Accumulated Expenses over 4 years: stood at $50.1 million in 2023, then advanced by 29.78% to $65.0 million in 2024, then grew by 2.54% to $66.6 million in 2025, then declined by 12.65% to $58.2 million in 2026.
• The last three Accumulated Expenses figures came in at $58.2 million (Q1 2026), $66.6 million (Q4 2025), and $49.5 million (Q3 2025), per Business Quant data.